NeoGenomics Stock - analyst consensus and long-term growth story

NeoGenomics stock currently trades without fresh corporate headlines, but analyst estimates and the company’s long-term diagnostics focus keep the name on the radar of healthcare investors. A look at consensus expectations, the business model and where the shares stand now.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 20:28 CET. Details in the imprint.

NeoGenomics (US64049M2098) draws investor attention today more for its position in cancer diagnostics than for fresh headlines. With no new company announcements or major filings visible on its investor relations page or top wire services, the focus shifts to consensus expectations and the long-term growth case.

What recent data show

NeoGenomics has not published a new SEC filing or press release since its most recent quarterly update and related materials in late April and early May, according to its investor relations site and the EDGAR database.

The last detailed figures came with first-quarter 2026 or late-2025 results, where management highlighted growth in oncology testing volumes and continued investment in advanced diagnostics platforms, as reflected in company presentations and prior filings.

Analyst views and consensus

Without a fresh Saturday headline, investors often look at Wall Street numbers: consensus data from major financial portals indicate that analysts still model revenue growth ahead of broader diagnostics peers and expect margins to gradually improve over the next several years.

Rating distributions compiled by broker aggregators show a mix of Buy and Hold recommendations on NeoGenomics shares, with recent target prices implying upside versus the current quote but also reflecting execution risks in scaling its testing network and managing reimbursement.

How the company makes money

NeoGenomics generates most of its revenue by providing cancer-focused clinical and advanced diagnostic testing services to oncologists, pathologists, hospitals and biopharma partners, including tests for solid tumors, hematologic malignancies and molecular profiling used to guide targeted therapies.

Where the stock trades today

The shares of NeoGenomics (US64049M2098) trade on the Nasdaq at $KURS as of KURS_DATUM.

Key facts on NeoGenomics stock

• Company: NeoGenomics Inc.
• ISIN: US64049M2098
• WKN: A2AB5C
• Ticker: NEO
• Venue: Nasdaq
• Price (as of KURS_DATUM): KURS USD
• Market cap: value USD (as of KURS_DATUM)
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Index membership: none of the major large-cap benchmarks such as the S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.